Mursla Bio

Oncology

Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.

News

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.